NCT05682560 — "Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome" trial site landscape

Public-registry site landscape for NCT05682560, “Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome”, a Long COVID study sponsored by StemCyte, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05682560 (registry record)
Study title	Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
Official title	A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
Sponsor	StemCyte, Inc.
Condition(s)	Long COVID; Post-COVID Syndrome; Post COVID-19 Condition
Phase	PHASE2
Listed sites	1
Intervention(s)	REGENECYTE, Placebo
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT05682560.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05682560 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →